Metabolic syndrome (MS) has been defined by the presence of a cluster of most dangerous risk factors, such as insulin resistance, hyperinsulinemia, and some combination of dyslipidemia and hypertension.
However, damages of renal structure and function have not been reported in this MS model. In fact, whether high-fat or high-fat, high-sucrose diet produced renal functional and pathological lesions is still conflicting. 7, 8) Nevertheless, several studies have demonstrated that high salt diet induces slightly hyperinsulinemia, moderately hypertension and renal damages in Sprague-Dawley (SD) rats. [9] [10] [11] Therefore, we hypothesized that long-term consumption of a high-fat, highsalt diet and sucrose solution in SD rats could induce a suitable animal model that mimics the basic characteristics of human MS and is helpful to understand the pathogenesis and therapy of nephropathy associated with MS.
Clinical and experimental studies have shown that losartan (angiotensin II receptor blocker, ARB) and pioglitazone (peroxisome proliferator-activated receptor-g, PPARg agonist) have renoprotective effects in diabetic nephropathy (DN) and non-diabetic renal diseases. [12] [13] [14] [15] [16] In addition, a recent study demonstrated that losartan and pioglitazone have synergistic renoprotective actions in patients with type 2 DN. 14) However, to our knowledge, there was no study on comparing the effects of losartan and pioglitazone combination therapy with monotherapy in MS nephropathy rats.
Vascular endothelial growth factor (VEGF) is an important growth factor involved in neoangiogenesis and vascular trophism. The dysregulation of VEGF signaling system has been identified in a wide variety of renal diseases, such as DN, glomerulonephritis, acute renal failure, chronic renal disease, and so on. [17] [18] [19] Qin et al. 13) suggested that losartan attenuates the overexpression of VEGF in DN rats. Lee et al. 20) demonstrated that pioglitazone has beneficial effects on DN in Otsuka-Long-Evans-Tokushima-Fatty rats by reducing the VEGF expression. Thus, we speculated that both drugs might improve renal damage in this MS model through attenuating dysregulation of the VEGF expression.
Therefore, the purposes of this study were: first, to establish a suitable animal model of nephropathy associated with MS; second, to evaluate the possible benefits of losartan and pioglitazone in this experimental MS nephropathy rats; third, to assess whether the combination therapy was superior to treatment with either drug alone; finally, to examine the role of VEGF express in losartan and pioglitazone-mediated renoprotection. vised 1996) . Rat chow was purchased from the Qinglongshan Experimental Animal Center (Nanjing, China). High-fat, high-salt (HFS) diet was prepared as described in our previous studies 21, 22) with slight modification. The diet components are listed in Table 1 .
MATERIALS AND METHODS

Drugs and Reagents
After the acclimatization period, seven rats (control group) received the normal diet and water, other rats were fed with the HFS diet and 20% sucrose solution ad libitum constant to the end of this experiment, namely lasted 16 weeks. After 8 weeks received the HFS diet and sucrose solution, the animals except the control group were randomly assigned to four groups, namely metabolic syndrome (MS) model group (nϭ7), losartan treatment group (20 mg/kg, nϭ6), pioglitazone treatment group (10 mg/kg, nϭ6), and combined treatment group (received both losartan and pioglitazone at the doses described above, nϭ6). The dosages of losartan 13, 23) and pioglitazone 24, 25) were based on previous studies. The drugs were orally administrated at 9:00-10:00 a.m. everyday by gavage for 8 weeks. Untreated groups received an equal volume of distilled water.
During the entire period of the experiment, body weight (BW), food consumption, and water intake were measured weekly. The rats were placed in metabolic cages to collect 24 h urine at the start, 8 weeks and end of this study. Systolic blood pressure (SBP) was measured monthly in conscious rats using the tail-cuff method (ALC-NIBP, Shanghai, China) as described in our previous studies. 21, 22) Two days before sacrifice, glucose tolerance was tested. At 16 weeks, the rats were fasted overnight and anesthetized by an intraperitoneal injection of 3% sodium pentobarbital (30 mg/kg). Blood samples were drawn from abdominal aorta, centrifuged to obtain serum. Kidneys were removed, decapsulated and immediately weighed. Visceral fat mass (mesenteric, epididymal and retroperitoneal adipose tissue) was excised and weighed. Kidney weight/body weight (KW/BW) ratio and visceral fat weight/body weight (VisF/BW) ratio were calculated. One kidney (the right one) was frozen at Ϫ80°C until processed, the other was removed for fixation in 10% formaldehyde for 24 h before process for histology.
Determination of Glucose Tolerance An oral glucose tolerance test (OGTT) was used to assess glucose tolerance. After 12 h fasting, tail blood samples were taken before (time 0) and 15, 30, 60, and 120 min after oral administration of a solution of 20% glucose (2 g/kg). Glucose levels were measured using a glucometer (One Touch Horizon, Life Scan Inc., U.S.A.). Animals were not anesthetized for this procedure.
Biochemical, Radioimmunoassay, and ELISA Analysis Levels of glucose, creatinine (Cr), total cholesterol, and triglycerides in serum and concentrations of protein and Cr in urine were determined by a biochemistry analyzer (Type-811, Shanghai, China) using commercial kits mentioned above. Serum insulin and urine albumin levels were measured using a Gamma-counter (GC-911, Hefei, China) with RIA kits. The sodium content in the urine was determined by an electrode method. Homeostatic model assessment of insulin resistance (HOMA-IR) 26) and creatinine clearance (Ccr) 27) were calculated using the following equations: HOMA-IRϭ[fasting glucose (mmol/l)ϫfasting insulin (mIU/ml)/22.5], and Ccr (ml/min/kg body weight)ϭ[urine Cr (mmol/l)ϫurine volume (ml)/serum Cr (mmol/l)]ϫ[1000/ body weight (g)]ϫ[1/1440 (min)].
Renal tissue were homogenized in RIPA lysis buffer (containing 1% protease inhibitor cocktail) and centrifuged (12000 g at 4°C for 15 min). The supernatant was used for ELISA and western blot analysis. Serum and renal VEGF levels were measured using a commercially ELISA kit according to the manufacturer's instructions. Briefly, the samples were transferred to 96-well microplates. The plate was incubated at 37°C for 1.5 h. Then, biotinylated anti-rat VEGF antibody was added to each well and incubated at 37°C for 1 h. After three washes, avidin-biotin-peroxidase complex was added and further incubated for 30 min. After washing further five times, TMB was added to each well and absorbency at 450 nm was measured using a microplate reader (ELX 800, BioTek, U.S.A.). Values of each sample were normalized with the protein concentrations measured using Bradford assay.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis Total RNA was extracted from the rat kidney using Trizol reagent (Gibco, U.S.A.) and converted to cDNA. The primer sequence of VEGF was selected accord- ing to a previous report 28) and was as follows: forward primer, 5Ј-GATGAGATAGAGTATATCTTCAAGCCGT-3Ј, and reverse primer: 5Ј-TCTATCTTTCTTTGGTCTGCATT-CAC-3Ј (210 bp). b-actin (401 bp) forward primer, 5Ј-CTC-CTGCTTGCTGATCCACATC-3Ј, and reverse primer: 5Ј-CCACTGCCGCATCCTCTT-3Ј.
The reaction of PCR was performed in a final volume of 50 ml containing cDNA (2 ml), deoxyribonucleotide triphosphate (dNTP) Mix (4 ml), Taq DNA polymerase (0.5 ml), forward and reverse primers (2 ml), 10ϫPCR buffer (5 ml) and DEPC water (36.5 ml). The conditions of PCR were as follows: initial denaturation was done at 95°C for 3 min and followed by 30 cycles of denaturation at 94°C for 30 s, 30 s of annealing at 58°C for VEGF, 55°C for b-actin, and 1 min for extension at 72°C. After the final cycle, the temperature was held at 72°C for 7 min to allow reannealing of amplified products. The PCR products were separated on a 1.5% agarose gel which was dried and then scanned using an ultraviolet gel imaging system (BioRad, U.S.A.). b-Actin was used as an internal control for the coamplification. The gene expression levels were normalized to the optical density of bactin in each sample.
Western Blot Analysis Western blotting was performed in the kidney from each group to detect VEGF protein levels. Equal amounts of protein (80 mg protein/lane) were separated by electrophoresis on a 12% sodium dodecyl sulfate polyacrylamide gel and transferred to a nitrocellulose membranes by electroblotting (Bio-Rad, U.S.A.). After blocking with 5% skim milk and 0.1% BSA in phosphate buffered saline (PBS) for 1 h, the membrane was incubated with VEGF and b-actin antibodies overnight at 4°C. The membrane was then washed and incubated with correspondent secondary peroxidase conjugated antibodies at 37°C for 1.5 h. The bands were detected using enhanced chemiluminescence kit (Pierce, Rockford, IL, U.S.A.) and evaluated by densitometry as described in our previous study.
22 ) The intensity of the bands was normalized to that of b-actin.
Histological Evaluation Kidney sections were stained with periodic acid Schiff (PAS) and Masson-trichrome, observed and photographed under a light microscope using the Image-Pro Plus 6.0 Software (Media Cybernetics, Inc., Silver Spring, MD, U.S.A.). Two pathologists examined the slides in a blind fashion, mixing the slides after covering the protocol numbers. The degree of glomerulosclerosis (GS) and tubulointerstitial injury was evaluated by a semi-quantitative method as described previously. 13, 29) Briefly, the GS score was assessed as: 0, no sclerosis; 1, sclerotic change less than 25%; 2, sclerosis of 25 to 50%; 3, sclerosis of 50 to 75%; 4, more than 75% of the glomerular tuft. The score of tubulointerstitial injury was assessed as: 0, no change; 1, 2, 3, and 4 when changes (inflammation, fibrosis, and tubular dilation) affected less than 25, 50, 75, or 100% of the field, respectively. At least 50 glomeruli or tubulointerstitial area (magnification, ϫ400) were randomly selected in each rat and the mean scores were calculated.
Statistical Analysis Data were expressed as meanϮ S.E.M. For statistical analysis, we used one-way analysis of variance (ANOVA) followed by Newman-Keuls tests. pϽ0.05 was considered statistically significant. Table 2 , at 16 weeks after received the HFS diet and 20% sucrose solution, the BW, water intake, VisF/BW, and KW, except for the food consumption and KW/BW ratio in the MS model group were significantly higher than those in the control group (pϽ0.05). Compared with the model group, the VisF/BW ratio was only reduced by treatment with pioglitazone (pϽ0.05), and the KW was decreased by treatment with losartan and the combination of losartan and pioglitazone (pϽ0.05). Other parameters were not significantly influenced by any of drug therapies.
RESULTS
Physiological Parameters As shown in
As shown in Fig. 1A , at the beginning (0 week) of the study, no significant difference in basal level of SBP was observed among all experimental groups. At 8 weeks, the SBP in rats fed with the HFS diet and 20% sucrose solution was moderately increased compared with that in the control rats (pϽ0.05). At 16 weeks, the SBP in the losartan, pioglitazone, and combined treatment group (113Ϯ7, 123Ϯ5, and 102Ϯ4 mmHg, respectively) was significantly lower than that in the model group (148Ϯ8 mmHg, pϽ0.05). Treatment with the combination had a further reduction in the SBP than administrated of either drug alone (pϽ0.05).
Biochemical Parameters As shown in Table 3 , Figs. 1B and D, at 16 weeks, the serum levels of insulin, total cholesterol and triglycerides, HOMA-IR, sodium excretion, and area under curve (AUC) of OGTT (area under the OGTT curve) in the model group were significantly increased compared with those in the control group (pϽ0.05). Treatment with pioglitazone and the combination of losartan and pioglitazone for 8 weeks obviously decreased the insulin, total cholesterol and triglycerides levels, HOMA-IR, and AUC of OGTT (pϽ0.05 versus model group). There were no significant differences in the glucose concentration, Ccr, sodium excretion and urinary protein excretion (UPE) among all experimental groups.
As shown in Fig. 1C , no significant difference in basal Fig. 2A , the serum level of VEGF protein was not significantly different among all experimental groups.
VEGF mRNA and Protein Expression in Kidney RT-PCR (Fig. 2C ) and Western blot (Fig. 2D) analysis demonstrated that mRNA and protein expression of VEGF in kidney was significantly decreased in the model group (reduced 56% and 38%, respectively, pϽ0.05 versus the control group). The VEGF mRNA and protein expression was not affected by treatment with losartan, pioglitazone, and their combination compared with the model group. The combination therapy did not result in a further upregulation of renal VEGF expression.
Renal Histopathology As illustrated in Fig. 3 , the MS rats displayed mild lesions of the glomeruli such as slight tuft adhesions and segmental sclerosis, with a GS score of 696 Vol. 34, No. 5 1.02Ϯ0.26 versus 0.16Ϯ0.05 in the control rats (pϽ0.05). The GS score was significantly lower in the losartan (0.66Ϯ0.10), pioglitazone (0.70Ϯ0.11) and combined treatment group (0.48Ϯ0.09) compared with the model group (pϽ0.05), the combination of both drugs superior to either alone (pϽ0.05). In addition, the MS rats exhibited no obviously tubulointerstitial damage (no tubular atrophy and interstitial fibrosis, and less than 1% of inflammation). There was no significant difference in the tubulointerstitial injury score among all experimental groups.
DISCUSSION
The major conclusions to be drawn from this study were: 1) SD rats fed with the HFS diet and 20% sucrose solution for 16 weeks could induced a suitable MS animal model associated with nephropathy, such as albuminuria and glomerulosclerosis; 2) treatment with the combination of losartan and pioglitazone provided synergistic effects in reducing SBP, UAE, and GS score when compared with monotherapy; and 3) the renal VEGF protein level, mRNA and protein expression were decreased in the MS rats, whereas not affected by both drugs, individually and in combination.
In the present study, at 8 weeks after received the HFS diet and 20% sucrose solution, rats showed a significant elevation in the BW (data not shown), SBP and UAE. In addition, Barnard et al. 5) demonstrated that consumption of high-fat, high-sucrose diet for 2 months induces hyperinsulinism and dyslipidemia in genetically normal rats. Thus, we considered that this animal model mimicked major features of the human MS at this time point, and the treated plan was to execute for the next 8 weeks. After received the abnormal diet for 16 weeks, the BW, VisF/BW, HOMA-IR, sodium excretion, AUC of OGTT and levels of serum insulin, total cholesterol and triglycerides were significantly increased in the MS model rats compared with the control rats. Furthermore, the MS model rats showed a significant elevation in the albuminuria and GS score, but the Ccr, UPE, and score of tubulointerstitial injury were not affected. Taken together, these data indicated that a valuable MS model was established and characterized by abdominal obesity, dyslipidemia, insulin resistance, hypertension, and relatively early stage of renal lesion.
The interesting finding of the present study was a synergistic effect in reduction of SBP after the combined treatment with losartan and pioglitazone. This finding was consistent with a recent report that pioglitazone enhances the antihypertensive effect of candesartan in Zucker obese rats fed a highprotein diet. 29) Several potential mechanisms would be involved in this synergistic effect. On the one hand, angiotensin II (ANG II) receptors are upregulated, leading to an increased sensitivity to ANG II on a high sodium intake. 30) Pioglitazone was reported to blunt the systemic response to ANG II and reduce the renal AT 1 R binding and expression in Zucker rats fed a high-salt diet. 31) On the other hand, it is well known that diminished nitric oxide (NO) production and increased oxidative inactivation contributing to endothelial dysfunction and maintenance of hypertension. Losartan and pioglitazone have been confirmed to reduce hypertension through upregulation of endothelial nitric oxide synthase (eNOS) expression and/or reduction of NO oxidative inactivation. 24, 32) Therefore, we speculated that losartan and pioglitazone produced a synergistic effect in reducing SBP were associated with further reduction in AT 1 R binding and expression and/or improvement in endothelial dysfunction. However, further studies should be carried out to evaluate these mechanisms. In addition, the dramatic synergistic antihypertensive effect of both agents might has the clinical risk in producing hypotension and postural hypotension, especially at high dose.
The accumulation of VisF is the most important cause of MS, and excess adipose tissue reduces insulin sensitivity in metabolically responsive tissues. Consistent with a recent study, 25) we demonstrated that pioglitazone significantly suppressed the increases in VisF accumulation in the MS rats. In our experimental conditions, we also found improvement in dyslipidemia and insulin resistance after treatment with pioglitazone, and these were the main causes contributed to the suppression of VisF/BW ratio. In addition, the similar effects were observed after the combination therapy. Taken together, the combination of losartan plus pioglitazone is equally effective compared to pioglitazone, but than losartan single applications concerning hypolipidemic effect and amelioration of insulin resistance.
Long-term administration of losartan, pioglitazone, and their combination reduced the UAE and GS score in the MS model rats. These results confirmed previous evidences that both losartan and pioglitazone have renoprotective effects. In addition, the renoprotection accompanying with obvious antihypertensive action was observed in all treatment groups. The combination therapy had a further antihypertensive effect than monotherapy, accompanied by a fall in albuminuria and GS score. Our study did not exclude that reduction in blood pressure per se and other effects might contribute to the renoprotective effects of losartan and pioglitazone. However, several studies have reported that reduction of blood pressure by hydralazine produces only a minimal beneficial renal effect in hypertensive Dahl salt-sensitive rats. 33) In normotensive streptozotocin-induced diabetic nephropathy rats, losartan and pioglitazone also ameliorate damages of renal function and histology through their pleiotropic actions, such as antioxidant and/or anti-inflammatory effects. 13, 34, 35) Thus, we considered that the renoprotective effect seen in this study was partially blood pressure-dependent.
VEGF exerts a very important and unique role in maintaining renal structure and functions. 36) Cancer patients treated with anti-VEGF therapy develope hypertension and renal damage such as proteinuria. 37, 38) Nevertheless, the role of VEGF in renal disease is controversial. There is a loss of VEGF in glomerulonephritis, acute renal failure, and chronic renal disease, [17] [18] [19] but an overabundance in DN. 13) In our study, at 16 weeks, we found lower VEGF protein level, mRNA and protein expression in kidney from the MS model group compared with the control group. Recent studies demonstrated that both glucose and ANG II increase renal VEGF expression. 39, 40) However, the serum level of glucose was not affected in our experimental conditions and thereby not contributed to the alteration of VEGF expression. ANG II is a powerful sodium-retaining hormone and vasoconstrictor that is decreased by high dietary sodium intake. 30) Gu et al. 41) reported that a long-term high salt diet decreases renal expression of VEGF mRNA and protein in SD rats. Taken together, downregulation of ANG II level induced by high sodium intake might contribute to the reduction of renal expression of VEGF in this animal model. Nevertheless, in contrast to our prediction, treatment with losartan, pioglitazone, and their combination for 8 weeks failed to enhance renal VEGF protein level, mRNA and protein expression. These results suggested that the renoprotective effect of both drugs in this MS model was due to other causes, such as reduction of renal AT 1 R binding and expression, 31, 42) upregulation of eNOS expression, improvement of oxidative stress, inhibition of inflammatory factors, and so on.
To date, whether or not an ARB and a PPARg agonist have synergistic renoprotective effects remains controversial. Only a recent study reported that there is no synergistic renoprotection between pioglitazone and L158809 (a new ARB) in unilateral ureteral obstruction rats. 16) In contrast, other studies demonstrated that a PPARg agonist enhances the renoprotective effect of an ARB in vivo and in vitro. 14, 29, 43) Consistent with these recent reports, in our experimental conditions, there was obvious evidence of a superiority of the combination therapy over individual therapies in ameliorating the albuminuria and renal structural damage. Xiao et al. 43) demonstrated that in human proximal tubular epithelial cells actived with immunoglobulin A (IgA) from patients with IgA nephropathy, dual treatment of rosiglitazone and losartan in vitro provides synergistic effects in reducing intercellular adhesion molecule-1 (ICAM-1), interleukin-6 (IL-6) and AT 1 R expression and nuclear factor-kB (NF-kB) and extracellular signal-regulated kinase (ERK)1/2 activation. Nevertheless, the precise mechanisms whereby the additional renoprotection provided by the combination of a PPARg agonist and an ARB were exerted in vivo required further investigations.
In summary, our results suggest that long-term orally administrated of the combination of losartan and pioglitazone offers additional potential advantages compared with monotherapy in reducing the elevated blood pressure and improving the lesions of renal structure and function in the HFS diet and sucrose solution induced MS nephropathy rats. Thus, it is likely that combined treatment with an ARB plus a PPARg agonist is beneficial in retarding the development of renal damage in patients with MS. However, given the limitation of animal model, whether this therapeutic strategy also works in humans requires further clinical investigations.
